Articles related to LYMPHOMA

The analysis showed that autologous stem-cell transplant (ASCT) was underutilized in the US community setting, among other results. These data support ongoing prospective trials evaluating the role of ASCT in patients achieving complete response without detectable minimal residual disease.

Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), is indicated for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies. Based on the results of a clinical trial evaluating the long-term effects of the drug, the FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs. prescribing an alternative therapy.

This report includes 3-year follow-up of the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL. At a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91%, with 68% complete responses. Medians for duration of response, progression-free survival, and overall survival were 28.2 months, 25.8 months, and 46.6 months, respectively. “These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.”

According to the researchers, “The findings from this study suggest that survivors of [HL] require life-long regular screening for early detection of chronic health conditions and that healthy lifestyle behaviors need to be strongly encouraged as these survivors appear more vulnerable to neurocognitive and psychosocial sequelae from these events.”

Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse. There was no difference in rates of receiving CRT.

Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.